Related by context. All words. (Click for frequent words.) 77 mCRC patients 72 mCRC 71 KRAS mutations occur 71 pegylated liposomal doxorubicin 70 metastatic renal cell carcinoma 70 relapsed MM 70 FOLFIRI 69 stage IIIb IV 69 pancreatic adenocarcinoma 68 mRCC 68 metastatic renal cell 68 SCCHN 68 HER2 positive metastatic breast 68 CR nPR 68 FOLFIRI alone 68 gemcitabine carboplatin 68 ErbB2 positive 68 follicular lymphoma FL 68 mutated KRAS 68 metastatic CRC 68 FOLFOX4 68 Flu Cy 67 fluoropyrimidine 67 infliximab monotherapy 67 sorafenib Nexavar ® 67 tumor xenograft models 67 chlorambucil 67 EGFR mutation positive 67 low dose cytarabine 67 5-FU/LV 67 Folfox 67 refractory chronic lymphocytic 67 leukemia CLL 67 Pemetrexed 67 cancer mCRC 67 HER2 positive cancers 67 locoregional recurrence 67 leukemia AML 67 FOLFOX6 67 plus dexamethasone 67 IFN α 66 small lymphocytic lymphoma 66 unresectable stage 66 recurrent NSCLC 66 NMIBC 66 XELOX 66 gemcitabine chemotherapy 66 nonsmall cell lung cancer 66 EGFR mutation 66 K ras mutations 66 metastatic GIST 66 carboplatin paclitaxel 66 refractory metastatic colorectal cancer 66 gemcitabine Gemzar 66 FOLFOX 66 TIMP 1 66 colorectal carcinomas 66 dacarbazine DTIC 66 anthracycline containing 65 hepatocellular carcinomas 65 squamous histology 65 Xelox 65 imatinib Gleevec ® 65 stage IIIA 65 epithelial tumors 65 recurrent metastatic 65 daunorubicin 65 EGFR TKI 65 K RAS 65 CIMZIA ™ 65 prostate carcinoma 65 KRAS status 65 Gleevec resistant 65 HGPIN 65 metastatic castration resistant 65 EGFR mutations 65 recurrent glioblastoma multiforme 65 plus gemcitabine 65 receptor tyrosine kinase inhibitor 65 Irinotecan 65 gefitinib Iressa 65 assessing T DM1 65 hepatocellular cancer 65 partial remissions 65 adriamycin 65 CHOP chemotherapy 65 KRAS mutations 65 naïve HCV 65 GSTP1 65 unresectable 65 underwent surgical resection 65 pomalidomide 65 recurrent glioblastoma 65 hA# 65 metastatic colorectal cancer 65 indolent follicular non 65 mcg albinterferon alfa 2b 65 stage IIIB 65 chemoresistant 65 locoregional disease 65 Amrubicin 65 TRAIL R1 65 oral clodronate 65 refractory chronic myeloid 65 HBeAg negative 65 idarubicin 65 cisplatin vinorelbine 65 pegylated interferon alpha 65 mutant KRAS 64 mutated K ras 64 nonmetastatic 64 imatinib resistant 64 hepatoma 64 PROSTVAC VF 64 relapsed refractory multiple myeloma 64 BRAF V#E mutation 64 bendamustine 64 galiximab 64 TTF Therapy 64 pT3 64 non squamous NSCLC 64 heavily pretreated patients 64 advanced NSCLC 64 Doxil ® 64 HCV genotype 64 CLL SLL 64 FLT3 ITD 64 gemcitabine cisplatin 64 metastatic hormone refractory 64 squamous 64 erlotinib Tarceva ® 64 mucinous 64 PEGylated Fab fragment 64 novel VDA molecule 64 FluCAM 64 resected pancreatic cancer 64 K ras gene 64 pCR 64 bleomycin 64 metaglidasen 64 liver metastasis 64 Aflibercept 64 colorectal carcinoma 64 cisplatin resistant 64 dasatinib Sprycel ® 64 1 diabetes T1D 64 thalidomide Thalomid 64 refractory NSCLC 64 trastuzumab Herceptin R 64 Multiple Myeloma MM 64 ovarian carcinoma 64 tumors GIST 64 dacarbazine 64 oblimersen 64 CYT# potent vascular disrupting 64 GISTs 64 lymphocytosis 64 biochemical recurrence 64 Camptosar ® 64 metastatic malignant 64 XIENCE V PROMUS Stent 64 metastatic pancreatic 64 peritoneal carcinomatosis 64 seminoma 64 T#I [002] 64 liver metastases 64 androgen independent 64 metastatic malignant melanoma 64 docetaxel chemotherapy 64 lenalidomide Revlimid R 64 telaprevir dosed 64 hematopoietic cancers 64 multiple myeloma MM 63 invasive ductal 63 HBeAg positive 63 5FU 63 taxane therapy 63 cytarabine daunorubicin 63 anthracycline taxane 63 asymptomatic metastatic 63 capecitabine Xeloda 63 trabectedin 63 subependymal giant cell 63 cell acute lymphoblastic 63 histological subtype 63 resectable 63 carcinoma HCC 63 decitabine 63 Temsirolimus 63 breast carcinomas 63 estramustine 63 biochemical relapse 63 pT2 63 relapsed acute myelogenous 63 chronic lymphocytic leukemia CLL 63 gastric adenocarcinoma 63 crizotinib PF # 63 FLT3 63 NNRTI resistance 63 biliary tract cancer 63 medically inoperable 63 xenograft models 63 Interferon alfa 63 Philadelphia Chromosome Positive 63 azacytidine 63 castrate resistant 63 HLA DR2 63 colon carcinoma 63 HER2 + 63 Follicular Lymphoma 63 irinotecan chemotherapy 63 melphalan prednisone 63 anti EGFR antibody 63 B CLL 63 Castration Resistant Prostate Cancer 63 Aplidin 63 sustained virological response 63 HER2 negative 63 metastatic colorectal 63 CC genotype 63 heavily pretreated 63 KRAS mutation 63 ELACYT 63 5 fluorouracil leucovorin 63 Fludara 63 interferon alfa 2a 63 malignant pleural mesothelioma 63 imatinib Gleevec 63 gastrointestinal stromal tumors 63 MAGE A3 ASCI 63 cyclophosphamide methotrexate 63 oral chemotherapeutic agent 63 lymphoid malignancies 63 imatinib therapy 63 relapsed SCLC 63 VELCADE melphalan 63 neoadjuvant therapy 63 MGd 63 MabCampath 63 Randomized Phase 63 chemoradiotherapy 63 SPRYCEL ® 63 adjuvant cisplatin 63 KRAS gene 63 acute leukemias 63 neoadjuvant chemotherapy 63 urothelial carcinoma 63 NY ESO 63 IV NSCLC 63 HBeAg negative patients 63 MYDICAR ® 63 ERBB2 63 Papillary 63 Relapsed Refractory 63 BRAF mutations 63 acute myeloid 63 alkylating agent 63 treatment naive genotype 63 demonstrated antitumor activity 63 KRAS mutant 63 breast carcinoma 63 metastatic androgen independent 63 K ras 63 liposomal doxorubicin 63 allogeneic bone marrow 63 plus dacarbazine 63 cisplatin gemcitabine 63 trastuzumab Herceptin ® 63 p# biomarker 63 histologic subtype 63 BRAF V#E 63 lymph node metastases 63 papillary renal cell carcinoma 63 chronic myeloid 63 refractory multiple myeloma 63 taxane refractory 63 HBsAg 63 Antitumor Activity 63 AEG# 63 remission induction 63 axitinib 62 complete cytogenetic response 62 non mutated KRAS 62 cisplatin chemotherapy 62 operable breast cancer 62 evaluating tivozanib 62 neoplasm 62 2 diabetes T2D 62 histologies 62 EGFR expressing mCRC 62 underwent resection 62 estrogen receptor ER 62 systemic ALCL 62 heterozygotes 62 diabetes mellitus DM 62 basal cell carcinoma BCC 62 Erlotinib 62 Glioblastoma multiforme GBM 62 Myelodysplastic Syndrome MDS 62 ER CHOP 62 Soft Tissue Sarcoma 62 gastrointestinal stromal tumor GIST 62 doxorubicin cyclophosphamide 62 adenocarcinomas 62 neoadjuvant 62 achieved sustained virological 62 CR CRu 62 achieved CCyR 62 5alpha reductase 62 rs# [002] 62 castrate resistant prostate cancer 62 bortezomib refractory 62 sarcomatoid 62 Glioblastoma Multiforme 62 infusional 5-FU/LV 62 Ph + acute lymphoblastic 62 bevacizumab Avastin ® 62 % CI #.#-#.# [007] 62 de novo AML 62 resectable pancreatic cancer 62 metastatic neuroendocrine tumors 62 diabetes mellitus T2DM 62 dasatinib Sprycel 62 metastatic RCC 62 colorectal liver metastases 62 T1c 62 taxane chemotherapy 62 oligodendrogliomas 62 HGS ETR1 mapatumumab 62 neuroblastoma tumors 62 postoperative chemotherapy 62 KRAS mutant tumors 62 cilengitide 62 Squamous 62 TACE 62 castration resistant prostate cancer 62 locoregional 62 systemic anaplastic large 62 placebo dexamethasone 62 nondiabetic patients 62 cytokeratin 62 EGFr 62 glioblastoma multiforme GBM 62 CD# + [001] 62 paclitaxel carboplatin 62 syngeneic 62 CANCIDAS 62 resistant hormone refractory 62 orthotopic model 62 autoantibody positive 62 HNSCC 62 distant metastasis 62 carboplatin chemotherapy 62 follicular lymphomas 62 seropositivity 62 IMA# 62 achieved ACR# 62 microsatellite instability 62 Median survival 62 BCG refractory 62 complete remissions 62 lung metastasis 62 free survival PFS 62 BRIM3 62 thymoma 62 acute myelogenous leukemia AML 62 recurrent glioblastoma multiforme GBM 62 cyclophosphamide doxorubicin vincristine 62 sunitinib Sutent ® 62 temsirolimus 62 5 FU leucovorin 62 log# copies mL 62 FOLFOX chemotherapy 62 antiangiogenic agent 62 alpha folate receptor 62 refractory AML 62 hormone receptor negative 62 grade cervical intraepithelial 62 PegIFN 62 amrubicin 62 advanced unresectable 62 HER2 overexpression 62 treatment naïve genotype 62 PEG IFN 62 % CI #.#-#.# [003] 62 Immunohistochemical staining 62 irinotecan doxorubicin oxaliplatin paclitaxel 62 eribulin mesylate 62 renal carcinoma 62 FOLFOX regimen 62 elevated LDH 62 follicular lymphoma 62 Ceplene/IL-2 62 chemoradiation therapy 62 metastatic bladder 62 recurrent GBM 62 sorafenib Nexavar 62 CIMZIA TM certolizumab pegol 62 DEB# 62 CCR5 tropic HIV 62 neurologic progression 62 HGS ETR1 62 invasive lobular 62 APOPTONE 62 lymphocytic 62 severe neutropenia 62 BRCA deficient 62 gefitinib 62 haematologic 62 platinum refractory 62 LHRH receptor positive 62 nonsquamous 62 differentiated thyroid 62 AVOREN 62 interferon gamma 1b 62 TORISEL 62 mycophenolate mofetil 62 cetuximab Erbitux ® 62 metastatic castrate resistant 62 comparator arm 62 pancreatic prostate 62 cytologically confirmed 62 metastatic HRPC 62 pediatric acute lymphoblastic 62 C#Y 62 metastatic colorectal carcinoma 62 hormone refractory prostate cancer 62 RECIST Response Evaluation Criteria 61 CIMZIA TM 61 carcinoembryonic antigen 61 adecatumumab 61 indolent NHL 61 non squamous 61 elacytarabine 61 AVASTIN 61 stage IIIB IV 61 Platinol ® cisplatin 61 metastatic carcinoma 61 pancreatic carcinoma 61 immunohistochemical staining 61 radiochemotherapy 61 aplastic anemia AA 61 completely resected 61 care regimens CCR 61 brain metastases 61 untreated metastatic melanoma 61 Fludarabine 61 NSCLC 61 TOP2A 61 Subgroup analysis 61 Metastatic Colorectal Cancer 61 lintuzumab SGN 61 previously untreated follicular 61 malignant lymphoma 61 ZACTIMA 61 non squamous histology 61 V#E 61 VEGFR2 inhibitor 61 advanced adenomas 61 CIN2 + 61 binary restenosis 61 PSMA ADC 61 mg q#h 61 papillary RCC 61 Adjuvant chemotherapy 61 5-fluorouracil/leucovorin 61 Response Evaluation Criteria 61 thyroglobulin 61 prostate cancer HRPC 61 ceftazidime 61 morphometric vertebral fractures 61 HBeAg seroconversion 61 dexamethasone Decadron 61 Gemzar ® 61 BRIM2 61 ACR# responses 61 LRAT 61 mg kg dose 61 EGFR protein 61 medullary thyroid cancer 61 micafungin 61 CCR5 delta# 61 anaplastic astrocytoma AA 61 durable remissions 61 ribavirin RBV 61 K#N 61 mapatumumab 61 preoperative chemotherapy 61 adjuvant tamoxifen 61 sodium glucose cotransporter 61 radiation sensitizer 61 squamous cell carcinoma SCC 61 FOLFOX6 chemotherapy regimen 61 MET amplification 61 tumor necrosis 61 cytogenetic responses 61 genotypic resistance 61 surgically resected 61 Platinol 61 BRAF mutation 61 FLT3 mutations 61 doxorubicin HCl liposome injection 61 Omacetaxine 61 follicular Non Hodgkin 61 lung metastases 61 standard chemotherapy regimens 61 antiretroviral naïve 61 evaluating T DM1 61 HCV genotypes 61 T#I mutant 61 PSADT 61 PI3K/Akt pathway inhibitor 61 stage IIIb 61 liposomal amphotericin B 61 kidney urologic 61 allogeneic stem cell 61 PSA nadir 61 hTERT 61 non metastatic resectable 61 FDG uptake 61 IFN beta 61 LV dysfunction 61 diagnosed glioblastoma multiforme 61 Hormone Refractory Prostate Cancer 61 peripheral blood mononuclear 61 achieve sustained virologic 61 follicular NHL 61 EndoTAGTM 1 61 lymph node metastasis 61 Anaplastic 61 FOLFOX4 alone 61 HER2/neu 61 ara C 61 CsA 61 refractory metastatic 61 xenograft tumors 61 phase IIb study 61 colorectal adenoma 61 thrombocytopenic 61 oral allopurinol 61 rhIGFBP 3 61 Refractory Hodgkin Lymphoma 61 Bezielle 61 BRAF inhibitor 61 chronic myeloid leukemia CML 61 prior chemotherapy regimens 61 standard chemotherapy regimen 61 Chronic Hepatitis C 61 IV melanoma 61 plus prednisone 61 pan HDAC inhibitor 61 registrational Phase 61 null responder 61 Ribavirin causes 61 Acute myeloid leukemia 61 heparanase 61 rituximab refractory 61 contralateral breast 61 CTAP# Capsules 61 fluvastatin 61 gemcitabine Gemzar ® 61 Pegylated Interferon 61 HBeAg 61 III EGFRvIII 61 histone deacetylase HDAC inhibitor 61 relapsing remitting 61 refractory ovarian cancer 61 mCRPC 61 lumiliximab 61 undetectable HBV DNA 61 prostate cancer PCa 61 noncarriers 61 unresectable locally advanced 61 leukemia ALL 61 LymphoStat B belimumab 61 refractory acute myeloid 61 microbiological eradication 61 recurrent colorectal cancer 61 nilotinib Tasigna ® 61 EGFRvIII 61 Haptoglobin 61 8mg/kg 61 radiation chemoradiation 61 plasma uric acid 61 Cutaneous T 61 Pertuzumab 61 metastatic lung cancer 61 orally administered inhibitor 61 refractory indolent non 61 nonalcoholic steatohepatitis NASH 61 sunitinib malate 61 Brentuximab Vedotin SGN 61 gemcitabine 61 HER2 expression 61 SSc 61 Cholangiocarcinoma 61 immunohistochemical 61 Albuferon TM 60 endometrioid 60 Sezary syndrome 60 Amplimexon 60 renal cell carcinomas 60 Bevacizumab 60 hypermethylated 60 BARACLUDE ® 60 KIF6 gene 60 gastrin analogue TT 60 Peginterferon 60 lymph node involvement 60 relapsed multiple myeloma 60 TNF blocker therapy 60 papillary 60 OncoVEX GM CSF 60 Imprime PGG 60 T2DM 60 cholangiocarcinoma 60 4mg/kg 60 HRPC 60 folinic acid 60 proteasome inhibitor 60 chemotherapy FOLFOX 60 gp# vaccine 60 lumbar spine BMD 60 log# reduction 60 trans retinoic acid ATRA 60 Glioblastoma Multiforme GBM 60 distant metastases 60 ongoing Phase 1b 60 CD# mAb 60 Mantle Cell Lymphoma 60 Chronic lymphocytic leukemia 60 liposomal formulation 60 Leukemias 60 highly emetogenic 60 Lenalidomide 60 essential thrombocythemia 60 somatostatin analog 60 histologically confirmed 60 T#I mutation 60 Fludara ® 60 CRp 60 metastatic gastric 60 CD3 + 60 adjuvant radiation 60 Median PFS 60 docetaxel prednisone 60 regorafenib 60 CCyR 60 Paraplatin ® carboplatin 60 chemotherapeutic regimens 60 PCa 60 MSH2 60 bortezomib 60 interferon IFN 60 EGFR HER2 60 sustained virologic response 60 HER2 receptor 60 macroalbuminuria 60 fallopian tube carcinoma 60 caspofungin 60 Peg IFN 60 CMV disease 60 CIN3 60 Solid Tumors criteria 60 concurrent chemoradiation 60 median PFS 60 genotype 1a 60 EGFR mutant 60 teriflunomide 60 relapsed leukemia 60 refractory CML 60 premalignant lesions 60 intravenous belinostat 60 hypereosinophilic syndrome 60 seliciclib 60 seronegative 60 pegylated interferon alfa 2a 60 Advanced Renal Cell 60 PKCi 60 gastrointestinal stromal tumor 60 JAK2 V#F 60 bevacizumab Avastin R 60 Annamycin 60 nonnucleoside reverse transcriptase inhibitors 60 B7 H3 60 Naive Patients 60 SOD2 gene 60 AGTR1 60 CALGB # [002] 60 confidence interval #.#-#.# 60 HIV coinfected 60 dose dexamethasone 60 carcinoid 60 pegylated interferon alfa 60 Hazard Ratio 60 vandetanib 60 cyclophosphamide chemotherapy 60 recurrent metastatic ovarian cancer 60 abacavir lamivudine 60 localized renal 60 NRTI resistance 60 nab paclitaxel 60 progression TTP 60 abnormal p# biomarker 60 advanced hepatocellular carcinoma 60 cetuximab Erbitux R 60 nodal metastasis 60 IRX 2 60 CDK inhibitor 60 histologically 60 Glioma 60 HER2 positive 60 pertuzumab 60 resected tumors 60 mutated p# 60 idraparinux 60 alvespimycin 60 Free Survival PFS 60 IgG1 monoclonal antibody 60 ritonavir boosted 60 untreated multiple myeloma 60 olmesartan 60 leukaemias 60 Pralatrexate 60 CDK4 60 monocytic 60 nanomolar 60 PegIFN RBV 60 ALT elevation 60 gastrointestinal stromal tumors GIST 60 Tamibarotene 60 T2 lesions 60 Thal Dex 60 dosing cohort 60 doxorubicin docetaxel 60 ABVD 60 Relapsed Refractory Multiple Myeloma 60 nonmelanoma skin cancers 60 oral ridaforolimus 60 metastatic HER2 negative 60 Hurthle cell 60 tumor histology 60 Ceflatonin 60 Trastuzumab 60 pheochromocytoma 60 ixabepilone 60 oral Hycamtin 60 immunotherapeutic agent 60 iniparib 60 NXL# 60 docetaxel Taxotere 60 Sipuleucel T 60 promoter methylation 60 interferon alfa 2b 60 poly ADP ribose polymerase 60 cyclin E 60 pamidronate 60 cytokine refractory 60 Camptosar ® irinotecan 60 renal tumors 60 Diffuse Large B 60 radical nephrectomy 60 Gastrointestinal Stromal Tumors 60 PROSTVAC ® 60 prospectively defined 60 pancreatic islet cell 60 Pharmacokinetics PK 60 REMICADE monotherapy 60 TRAF1 C5 60 enzastaurin 60 Xanafide 60 -#.# log# 60 soft tissue sarcomas 60 DFMO 60 PD LID 60 dasatinib 60 Randomized Phase II 60 hepatitis C genotype 60 relapsed refractory AML 60 #.#ng/ml 60 Velcade bortezomib 60 chronic HCV genotype 60 interferon α 60 Bortezomib 60 EOquin TM 60 nucleoside analogue 60 ADPKD 60 Epratuzumab 60 Capecitabine 60 HLA DR4 60 Acute lymphoblastic leukemia 60 situ LCIS 60 milatuzumab 60 PAOD 60 EGFR receptor 60 F FLT 60 ug dose 60 virologic response 60 rALLy 60 Canvaxin TM 60 chemotherapy cisplatin 60 relapsed myeloma 60 Bevacizumab Avastin 60 antithymocyte globulin 60 % Confidence Interval 60 interferon alfa 60 recurrent malignant glioma 60 cell adhesion molecule 60 atypical hyperplasia 60 GPNMB 60 clinically localized prostate 60 RRM1 60 Peginterferon Alfa 2a 60 receptor blocker 60 antibody titer 60 adjunctive placebo 60 Peginterferon alfa 2b 60 hepatorenal syndrome 60 cediranib 60 histologic 60 HER2 amplified 60 MCyR 60 Kaplan Meier analysis 60 satraplatin Phase 60 oral squamous cell 60 resminostat 60 cabazitaxel 60 prostate cancer CaP 60 malignant ovarian 60 patients evaluable 60 affective psychosis 60 dose cohort 60 pemetrexed 60 myelofibrosis polycythemia vera 60 mg BID dose 60 selective modulator 60 lintuzumab 60 PKC# 60 receiving VICTRELIS 60 definite stent thrombosis 60 GW# [003] 60 tipranavir ritonavir 60 seropositive patients 60 EGFR TK 60 TO AVOID PREGNANCY WHILE 60 erlotinib 59 epirubicin 59 vidofludimus 59 Neuvenge 59 anastrazole 59 registrational trial 59 BR.# 59 relapsing remitting MS RRMS 59 Natalizumab 59 antibody MAb 59 factor receptor EGFR 59 elevated triglyceride levels 59 Metastatic breast cancer 59 refractory CTCL 59 paclitaxel cisplatin 59 temozolomide TMZ 59 seminal vesicle invasion 59 Vidaza ® 59 remission CR 59 basiliximab 59 huN# DM1 59 anti leukemic 59 refractory cutaneous T 59 smoldering myeloma 59 chemoembolization 59 immunomodulatory therapy 59 CTEPH 59 familial amyloidotic polyneuropathy FAP 59 estrogen receptor progesterone receptor 59 CDH1 59 induces apoptosis 59 thymalfasin 59 LEXIVA r 59 adalimumab 59 Panzem R NCD 59 HER2 neu 59 Surgical resection 59 fludarabine 59 Cell Lymphoma 59 Seliciclib 59 paroxysmal AF 59 R sorafenib tablets 59 Stage IIB 59 plus OBT 59 malignant neoplasm 59 LUX Lung 59 APOL1 59 erlotinib Tarceva 59 HGS ETR2 59 ® cetuximab 59 Halaven 59 ZOLINZA 59 goserelin 59 Hodgkin lymphoma HL 59 certolizumab 59 TTR gene 59 FUSILEV enhances 59 Her2/neu 59 virus HCV protease inhibitor 59 mTOR inhibitor 59 Stage IIIb 59 methotrexate monotherapy 59 G#DT 59 cervical carcinoma 59 sunitinib Sutent 59 Hycamtin ® 59 Aptivus ® 59 bevacizumab Avastin 59 Immunohistochemical analysis 59 Fluorouracil 59 KRAS mutation status 59 irinotecan cisplatin 59 ovarian pancreatic 59 variant allele 59 alfa 2a 59 Lenocta 59 Elitek 59 peginterferon alfa 2b 59 unresectable tumors 59 tumor shrinkage 59 pancreatic endocrine 59 response pCR 59 mitoxantrone chemotherapy 59 intestinal metaplasia 59 undergoing hematopoietic stem 59 neoadjuvant radiation 59 multivariate Cox 59 paclitaxel eluting stents 59 TRAIL R2 59 Alkeran 59 nodular partial response 59 HLA DR4 immune 59 unresectable Stage III 59 XmAb# 59 relapsed ovarian cancer 59 posaconazole 59 NOD SCID mice 59 paclitaxel Taxol 59 systemic lupus erythematosus SLE 59 lactate dehydrogenase LDH 59 progesterone receptor PR 59 non metastatic osteosarcoma 59 orthotopic 59 mg ustekinumab 59 CML CP 59 eribulin 59 aminotransferase levels 59 evaluating picoplatin 59 myeloproliferative 59 Median progression 59 randomized Phase III 59 Nilotinib 59 TIMP 59 xenografts 59 gastrointestinal stromal tumors GISTs 59 achieved mucosal healing 59 node metastases 59 fluorouracil leucovorin 59 Kit CD# positive 59 ependymoma 59 median survivals 59 chronic HCV 59 tumor xenografts 59 NPM1 mutations 59 CDKN2A 59 pancreatic NET 59 nilotinib 59 Gemcitabine 59 vincristine doxorubicin 59 Temodar ® 59 rs# [004] 59 preoperative PSA 59 prostate adenocarcinoma 59 MGUS 59 carcinoids 59 paclitaxel Taxol ® 59 Copegus ribavirin 59 MALT lymphoma 59 tocilizumab 59 HLA DR 59 Cloretazine 59 lymphadenectomy 59 PTHrP 59 ELOXATIN 59 predictive biomarker 59 CD# expressing 59 proliferator activated receptor 59 HCV SPRINT 59 Acute Myeloid Leukemia AML 59 FOLPI 59 low dose dexamethasone 59 GV# [001] 59 minimally symptomatic 59 Unresectable